Corcept Therapeutics (NASDAQ:CORT – Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $67.00 to $60.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 48.37% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. UBS Group assumed coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $76.00.
Get Our Latest Report on Corcept Therapeutics
Corcept Therapeutics Stock Up 19.6%
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. During the same period in the prior year, the business earned $0.26 EPS. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Research analysts predict that Corcept Therapeutics will post 1.36 EPS for the current year.
Insider Buying and Selling
In other Corcept Therapeutics news, Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Guyer sold 20,000 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. The trade was a 94.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 60,000 shares of company stock valued at $2,241,035 over the last three months. Corporate insiders own 20.50% of the company’s stock.
Institutional Investors Weigh In On Corcept Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Pathstone Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after buying an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. lifted its stake in Corcept Therapeutics by 0.5% during the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock valued at $2,953,000 after purchasing an additional 170 shares during the last quarter. Clearstead Advisors LLC boosted its holdings in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares in the last quarter. Gould Capital LLC lifted its position in shares of Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in shares of Corcept Therapeutics by 1.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock worth $1,390,000 after acquiring an additional 237 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Corcept Therapeutics
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: FDA approval for relacorilant (Lifyorli) + nab‑paclitaxel opens a new commercial indication (platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer). This is the clear immediate catalyst for buying interest — approval arrived ahead of prior timelines and creates a concrete revenue opportunity for Corcept’s lead drug. FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab‑Paclitaxel for Treatment of Patients with Platinum‑Resistant Ovarian Cancer
- Positive Sentiment: Analyst support: H.C. Wainwright reiterated a Buy and set a $60 target, signaling sell‑side backing for upside based on the approval and longer‑term sales potential. Analyst commentary likely reinforced investor demand. Corcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
- Positive Sentiment: Insider buying and renewed focus on relacorilant’s regulatory path have supported momentum — a director’s disclosed open‑market purchase and renewed regulatory catalysts helped convince traders that management/patient insiders see value ahead. That positioning amplified the rally. Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst
- Neutral Sentiment: Trading mechanics: the stock experienced a Regulatory LULD pause (trading halt) during the intraday move — a routine market safeguard during large price swings that can intensify short‑term volatility.
- Neutral Sentiment: Widespread media coverage amplified intraday momentum as outlets reported the approval and the rapid price reaction; high volume and short‑covering likely intensified the move. What’s Behind The Jump In Corcept Therapeutics Stock?
- Negative Sentiment: Litigation risk: multiple law firms have filed/are soliciting plaintiffs in securities class actions tied to past regulatory issues and alleged disclosure problems (lead‑plaintiff deadlines in April). Ongoing litigation can create legal expenses, distraction, and investor uncertainty. Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) – Deadline on April 21, 2026
- Negative Sentiment: Insider selling: a disclosed sale by William Guyer (reported March 20) reduced his holdings materially; such sales can be read negatively by some investors even when not unusual or pre‑planned. Insider trade details for William Guyer
About Corcept Therapeutics
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
See Also
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
